MDV Expands Team Pursuing Advances in Personalize...( MENLO PARK Calif. Nov. 20 /- MDV-Mohr...)

MENLO PARK, Calif., Nov. 20 /PRNewswire/ -- MDV-Mohr Davidow Ventures, a leading Silicon Valley venture capital firm, today announced the addition of Phyllis Whiteley and Dan Riskin to the firm as Executive-in-Residence and Entrepreneur-in-Residence, respectively. Each will pursue and develop start-up opportunities that provide healthcare providers and consumers more effective ways to manage health and wellness -- from prevention to diagnosis to the treatment of disease.

(Logo: http://www.newscom.com/cgi-bin/prnh/20070702/AQM026LOGO)

"Phyllis and Dan bring important domain expertise and experience to the MDV team," said MDV General Partner Sue Siegel. "They will strengthen MDV's current investing activities in personalized medicine and expand our reach into new areas including health information systems, Health 2.0 businesses, and into the emerging area of consumer-driven medicine."

Phyllis Whiteley brings more than 20 years experience across academics, biotech, and pharma in research, development, business, and portfolio management. Most recently she worked with 5AM Ventures where she co-founded Anaphore, Inc. Prior to her work in venture capital, Whiteley was an Officer and Senior Vice President at Perlegen Sciences, Inc. Before Perlegen, she served as Vice President, Strategic Portfolio Management for F. Hoffman La Roche. During her ten years with Roche, she held various senior management positions. Prior to her Roche tenure, Whiteley was a senior research immunologist at Merck. She holds a Ph.D. in Pharmacology from Washington University, St. Louis, Missouri. Whiteley serves on several private company boards and is on the board of the Personalized Medicine Coalition.

Dan Riskin will focus on healthcare information systems and business models as an EIR (Entrepreneur-In-Residence). He brings a di
'/>"/>